Vir Biotechnology, Inc. (VIR) Form 8-K — Oct 1, 2026

Vir Biotechnology announced on October 1, 2026 the appointment of Aziz Sawaf as Executive Vice President and Chief Financial Officer, effective October 5, 2026. Sawaf joins from Theravance Biopharma, where he served as CFO since 2023, and previously held finance roles at Gilead Sciences. Brent Sabatini, who had been serving as interim principal financial officer, will continue as Senior Vice President and Chief Accounting Officer. Sawaf's compensation includes a $520,000 base salary, a 45% target bonus, a $150,000 sign-on bonus, and equity awards of 150,000 options and 75,000 RSUs vesting over four years.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.